Abstract
s / Biol Blood Marrow Transplant 21 (2015) S206eS239 S230 Results: Five patients with PIDD who underwent HSCT were recruited to date, and two have been infused with VSTs at 5x10E6 cells/m2/dose. The manufactured VSTs had a CD4+ Tcell predominance with detectable antiviral activity against CMV pp65/IE1, EBV-LMP2/EBNA1, and Adv-Hexon/Penton epitopes based on IFN-g ELISpot assays. All VSTs were nonalloreactive in chromium release assays utilizing allogeneic PHA blasts as targets ( 1,000,000 to<1000 copies/ml. The second patient was treated for CMV viremia after matched sibling HSCT for MHC-II deficiency, and had viral clearance of CMV within 1-month post-VST infusion. One patient developed Grade I skin GVHD post VSTs which resolved within 1 week and was associated with the tapering of immune suppression. Conclusions: VSTs are safe and effective for control of viral infections in patients with PIDD following HSCT. We plan further evaluation of virus-specific CTL for patients with PIDD both before and after HSCT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
